Furthermore, Interleukin-6 (IL-6) deficiency alleviates neuroinflammation, reduces Aβ deposition, and improves cognitive function by inhibiting the STAT3-cGAS-STING pathway, thereby providing a potential therapeutic target for AD treatment [43]. The gene discussed is CGAS; the disease is Alzheimer disease.